Close
Nordic 9Nordic 9

Charcot-Marie-Tooth Research Foundation (investor - Others)

United States cmtrf.org
See something wrong or missing? Let us know
Offices:Atlanta
Average round investment:49.62M USD
Average number per year:1.0
Distribution: 2025 (1)2024 (1)
Portfolio companies: Belgium Augustine Therapeutics
Mostly invests in: Belgium Belgium (2) Biotech (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Charcot-Marie-Tooth Research Foundation

Name Criteria
Belgium Gemma Frisius Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
United Kingdom Isomer Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
China China Grand Pharmaceutical and Healthcare Holdings
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Global Emerging Markets
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Switzerland MTIP AG
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Belgium BNP Paribas Fortis Private Equity
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
France CPH Banque
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Sweden Trill Impact
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
Belgium Gimv
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 2.3
  • Active last 12 months: Yes
Switzerland BioMedPartners
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 2.4
  • Active last 12 months: Yes
Top